Methimazole Use in Pregnancy
Methimazole should be used ONLY after the first trimester of pregnancy (starting at week 16 or beginning of second trimester) due to rare but documented teratogenic effects during organogenesis; propylthiouracil is the preferred antithyroid drug during the first trimester. 1, 2, 3
Trimester-Specific Approach
First Trimester (Weeks 0-13)
Avoid methimazole - associated with rare congenital malformations including:
Second and Third Trimesters (Week 16 onward)
- Switch from PTU to methimazole at the beginning of the second trimester 1, 2
- This switch is recommended because PTU carries risk of rare but potentially fatal hepatotoxicity 1
- The FDA specifically recommends this trimester-based approach 1, 3
Dosing Strategy
Conversion from PTU to Methimazole
- Potency ratio: 20-30:1 (PTU:MMI)
- Example: 300 mg PTU = approximately 10-15 mg methimazole 1
- Monitor thyroid function 2 weeks after switching, then every 2-4 weeks 2
Target Dosing
- Use the LOWEST effective dose to maintain maternal euthyroidism 1
- Starting dose when initiating in second trimester: 5-10 mg daily 4
- Do NOT use block-replacement therapy (antithyroid drug + levothyroxine) in pregnancy 1
Monitoring Requirements
Thyroid Function Targets
Keep maternal free T4 at or slightly ABOVE the upper limit of normal (non-pregnant reference range) 1, 2
Alternative targets:
- Total T4: 1.5 times upper limit of normal range 2
- TSH may remain suppressed throughout pregnancy - do not use TSH alone to guide therapy 1
Monitoring Frequency
- Monthly thyroid function tests throughout pregnancy 1
- Initially every 2 weeks after starting or switching medications, then every 2-4 weeks 4, 2
- More frequent monitoring (every 2-4 weeks) when switching between drugs 4
Additional Monitoring
- TRAb (thyroid receptor antibodies) should be measured:
Critical Pitfalls to Avoid
Fetal hypothyroidism risk: Even when mother is euthyroid, excessive antithyroid drug doses can cause fetal goiter and hypothyroidism in second/third trimesters when fetal thyroid is functioning 1
Switching complications: Changing between PTU and methimazole can destabilize thyroid control due to pharmacokinetic differences 1, 4
Alternative to switching: If hyperthyroidism improves significantly during pregnancy allowing dose reduction or discontinuation, continuing PTU throughout pregnancy is acceptable rather than switching 4
Hepatotoxicity monitoring: If PTU is continued beyond first trimester, monitor liver enzymes every 4 weeks, though this doesn't prevent fulminant hepatotoxicity 1
Special Circumstances
Pre-existing Methimazole Use
Women already on methimazole who become pregnant should:
- Obtain pregnancy test at earliest suspicion of pregnancy 1
- Switch to PTU immediately in first trimester 1
- Switch back to methimazole at beginning of second trimester 1
Breastfeeding
- Methimazole is PREFERRED over PTU during lactation 1, 3
- Safe at doses ≤10 mg/day 4
- No adverse effects on infant thyroid function or neurodevelopment documented 1, 3
Surgery Indication
Thyroidectomy during pregnancy is reserved for:
- Severe adverse reaction to antithyroid drugs
- Persistently high doses required (>30 mg/day methimazole)
- Non-adherence with uncontrolled hyperthyroidism
- Optimal timing: second trimester 1, 2
Rationale for Trimester-Based Approach
The evidence clearly shows methimazole's teratogenic effects occur during first-trimester organogenesis, while PTU's hepatotoxic risk persists throughout treatment. This creates a risk-benefit crossover at the end of the first trimester, justifying the switch despite potential for thyroid instability 1, 2, 3.